Navigation Links
Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Date:5/21/2009

NANJING, China, May 21 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has applied for two Chinese patents for its flagship product, Cisatracurim besylate, a pre-surgical skeletal muscle relaxant.

The Company has applied to China's State Intellectual Property Office (SIPO) for a Chinese patent for Atracurium's freeze-drying compounds (Application Number 200710127756.2; "Atracurium's freeze-drying compounds"). This patent has already been published and is now awaiting certification.

The Company has also applied to SIPO for a Chinese patent for the preparation for separating and purifying Cisatracurim besylate through HPLC (Application Number 200910028198.3; "The preparation for separating and purifying Cisatracurim besylate through HPLC"). Using this method, the Company will reduce manufacturing costs and improve product quality.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
2. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
3. Sinobiopharma Secures Rights to Seven Key Patents
4. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma, Inc. Appoints New Director of Marketing
7. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Saddam Lawyer Applies for Pardon for Dr Crippen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs ... the Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old ... failed conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is ...
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point ... continues to grow. CSM has doubled in size over the past six months ... growth strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... and further enhances its scientific power by providing investigators access to a ... agreed to join the scientific advisory board. “We are committed to offering ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM ... firm for the life sciences and healthcare industries, is honored that Jay ... Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role in ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):